샘플 요청 목록

 카트 문의
시장보고서
상품코드
1774874

세계의 유전자 벡터 시장

Gene Vector
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 480 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 유전자 벡터 시장은 2030년까지 30억 달러에 도달

2024년에 15억 달러로 추정되는 유전자 벡터 세계 시장은 분석 기간인 2024-2030년 CAGR 12.7%로 성장하여 2030년에는 30억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 플라스미드 DNA 벡터는 CAGR 15.3%를 나타내고, 분석 기간 종료시에는 9억 5,910만 달러에 이를 것으로 예측됩니다. 아데노바이러스 벡터 부문의 성장률은 분석 기간중 CAGR 9.6%로 추정됩니다.

미국 시장은 4억 570만 달러로 추정, 중국은 CAGR 17.4%를 보일 것으로 예측

미국의 유전자 벡터 시장은 2024년에 4억 570만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 6억 5,570만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 17.4%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 9.0%와 11.4%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 10.1%로 성장할 전망입니다.

세계의 유전자 벡터 시장 - 주요 동향과 촉진요인 정리

유전자 치료와 유전공학의 발전에 유전자 벡터가 필수적인 이유는 무엇일까?

유전자 벡터는 현대 유전자 치료의 근간이 되고 있으며, 유전성 질환의 교정, 면역 반응 강화, 치료 목적의 세포 공학을 위해 표적 세포에 유전 물질을 전달할 수 있게 해줍니다. 이들 벡터는 변형된 유전자를 숙주 세포에 도입하는 매개체 역할을 하며, 면역계의 거부반응 없이 효율적인 유전자 발현을 보장합니다. 유전자 벡터는 주로 바이러스성과 비바이러스성 두 가지 유형이 있으며, 유전자 도입의 효율성, 안정성, 안전성에서 각각 다른 장점을 가지고 있습니다.

아데노부수체 바이러스(AAV), 렌티바이러스, 레트로바이러스 등의 바이러스성 벡터는 높은 도입 효율과 장기적인 유전자 발현 능력으로 인해 유전자 치료에 널리 사용되고 있습니다. 지질 나노입자, 일렉트로포레이션, 폴리머 기반 캐리어를 포함한 비바이러스성 벡터는 특히 RNA 기반 치료 및 CRISPR을 통한 유전자 편집에서 보다 안전한 대안으로 각광받고 있습니다. 개인 맞춤형 치료, 암 면역치료, 희귀질환 치료의 부상으로 유전자 벡터는 정밀의료와 재생의료에 혁명을 일으키는 데 중요한 역할을 하고 있습니다.

유전자 벡터 수요를 주도하는 산업과 용도는?

제약 및 생명공학 분야는 유전자 벡터의 가장 큰 수요처로, 유전자 치료, 세포 치료, 백신 개발에 이러한 전달 시스템을 활용하고 있으며, CAR-T 세포 치료의 급속한 확대로 인해 렌티바이러스 및 레트로바이러스 벡터가 암 치료용 T세포를 생성하는 암 치료용 T세포를 생산하기 위해 렌티바이러스 벡터와 레트로바이러스 벡터가 사용되면서 고품질 벡터 제조에 대한 수요가 크게 증가하고 있습니다. 또한, 유전자 벡터는 재생의료에 필수적이며, 조직 복구 및 장기 재생을 위한 줄기세포 변형을 촉진합니다.

유전자 벡터는 헬스케어뿐만 아니라 유전자 변형 작물이나 가축을 위한 농업 생명공학에서도 연구되고 있습니다. 합성생물학의 발전은 또한 대사 경로 공학에 유전자 벡터를 활용하여 바이오연료, 생분해성 플라스틱, 고부가가치 바이오 소재의 생산을 가능하게 하고 있습니다. 유전자 도입을 최적화하기 위한 AI 기반 벡터 설계와 차세대 염기서열 분석(NGS)의 채택이 증가하면서 연구와 상업적 적용이 더욱 가속화되고 있습니다. 유전자 편집과 세포 기반 치료가 계속 확대되는 가운데, 유전자 벡터 기술은 유전자 혁신의 핵심이 될 것으로 예측됩니다.

유전자 벡터 개발의 최신 기술 발전은?

최근 기술 발전으로 유전자 벡터의 효율성, 특이성, 안전성이 크게 향상되었습니다. 가장 주목할 만한 돌파구 중 하나는 차세대 AAV 벡터의 개발입니다. 이 벡터는 조직 지향성이 우수하고 면역원성이 감소되어 부작용을 최소화한 표적 유전자 도입이 가능합니다. 또한, 자가증폭 RNA(saRNA) 벡터는 백신 개발, 특히 mRNA 기반 플랫폼에서 인기를 끌고 있으며, 저용량으로 장시간 단백질 발현을 가능하게 합니다.

비바이러스성 벡터 분야에서는 지질 나노입자(LNP) 기술이 RNA 치료제에 혁명을 일으켜 백신 및 유전자 편집 용도에서 유전물질을 전달할 수 있는 고효율의 확장 가능한 방법을 제공합니다. 또한, AI를 이용한 벡터 공학은 합성 프로모터 설계를 개선하고 유전자 발현 제어를 강화하며 오프 타겟 효과를 감소시켰습니다. 또한, CRISPR 기반 유전자 편집의 발전으로 주변 DNA 서열을 파괴하지 않고 특정 유전자 변이를 선택적으로 편집할 수 있는 정밀 유도 벡터를 개발할 수 있게 되었습니다. 이러한 기술 혁신은 유전자 치료를 보다 안전하고, 보다 효과적이며, 보다 광범위하게 적용할 수 있게 하여 유전자 치료의 전망을 재구성하고 있습니다.

유전자 벡터 시장의 성장을 가속하는 요인은 무엇인가?

유전자 벡터 시장의 성장은 유전성 질환의 유병률 증가, 유전자 치료에 대한 투자 증가, 벡터 제조 기술의 발전 등 여러 요인에 의해 주도되고 있으며, Luxturna와 Zolgensma와 같은 FDA 승인 유전자 치료제의 성공은 유전자 벡터 기반 치료의 임상적 잠재력을 입증하여 추가 연구를 촉진하고 있습니다. 유전자 벡터 기반 치료의 임상적 가능성을 입증하고, 추가적인 연구 개발을 촉진하고 있습니다. 또한, 확장 가능하고 GMP를 준수하는 벡터 제조에 대한 수요는 바이러스 및 비바이러스 벡터 제조를 전문으로 하는 위탁개발생산기관(CDMO)의 확대로 이어졌습니다.

맞춤형 의료와 차세대 면역치료의 부상도 고정밀 유전자 도입 시스템의 필요성에 박차를 가하고 있습니다. 규제 당국이 유전자 치료의 신속한 승인 경로를 도입함에 따라 제약사들은 첨단 벡터 개발에 투자하고 있습니다. 또한, 벡터 최적화에 AI와 계산 모델링을 통합하여 효율성을 높이고 생산 비용을 절감하고 있습니다. 종양학, 신경학, 희귀질환에서 유전자 치료에 대한 수요가 지속적으로 증가함에 따라 유전자 벡터 시장은 지속적으로 성장하여 유전자 의료 및 바이오 의약품 혁신의 미래를 형성할 것으로 예측됩니다.

부문

벡터 유형(플라스미드 DNA 벡터, 아데노바이러스 벡터, 아데노 부속 바이러스 벡터, 레트로바이러스 벡터, 렌티바이러스 벡터, 기타 벡터 유형), 질환(암, 유전자 질환, 감염증, 기타 질환), 용도(유전자 치료 용도, 백신 요법 용도, 기타 용도), 최종 용도(CDMOS 최종 용도, 제약 기업 및 바이오테크놀러지 기업 최종 용도, 연구기관 최종 용도, CRO 최종 용도)

조사 대상 기업 예

  • 4D Molecular Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Bluebird Bio
  • Catalent Biologics
  • Charles River Laboratories International Inc
  • CRISPR Therapeutics AG
  • Editas Medicine
  • FUJIFILM Holdings Corporation
  • Generation Bio
  • Intellia Therapeutics
  • Kaneka Corporation
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Oxford Biomedica plc
  • Rocket Pharmaceuticals
  • Sarepta Therapeutics
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • WuXi AppTec

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global Gene Vector Market to Reach US$3.0 Billion by 2030

The global market for Gene Vector estimated at US$1.5 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2024-2030. Plasmid DNA Vector, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$959.1 Million by the end of the analysis period. Growth in the Adenoviral Vector segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$405.7 Million While China is Forecast to Grow at 17.4% CAGR

The Gene Vector market in the U.S. is estimated at US$405.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$655.7 Million by the year 2030 trailing a CAGR of 17.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Gene Vector Market - Key Trends & Drivers Summarized

Why Are Gene Vectors Essential for Advancing Gene Therapy and Genetic Engineering?

Gene vectors have become the backbone of modern gene therapy, enabling the delivery of genetic material into target cells to correct genetic disorders, enhance immune responses, or engineer cells for therapeutic purposes. These vectors serve as vehicles that transfer modified genes into host cells, ensuring efficient gene expression without triggering immune system rejection. The two primary types of gene vectors-viral and non-viral-offer distinct advantages in gene transfer efficiency, stability, and safety.

Viral vectors, such as adeno-associated viruses (AAVs), lentiviruses, and retroviruses, are widely used in gene therapy due to their high transduction efficiency and long-term gene expression capabilities. Non-viral vectors, including lipid nanoparticles, electroporation, and polymer-based carriers, have gained traction as safer alternatives, particularly for RNA-based therapies and CRISPR-mediated gene editing. With the rise of personalized medicine, cancer immunotherapies, and rare disease treatments, gene vectors are playing a critical role in revolutionizing precision healthcare and regenerative medicine.

Which Industries and Applications Are Driving Demand for Gene Vectors?

The pharmaceutical and biotechnology sectors are the largest consumers of gene vectors, leveraging these delivery systems for gene therapy, cell therapy, and vaccine development. The rapid expansion of CAR-T cell therapies, which rely on lentiviral and retroviral vectors to engineer T cells for cancer treatment, has significantly increased demand for high-quality vector manufacturing. Additionally, gene vectors are essential in regenerative medicine, where they facilitate stem cell modification for tissue repair and organ regeneration.

Beyond healthcare, gene vectors are being explored in agricultural biotechnology for genetically engineered crops and livestock. Advances in synthetic biology are also utilizing gene vectors for metabolic pathway engineering, enabling the production of biofuels, biodegradable plastics, and high-value biomaterials. The increasing adoption of AI-driven vector design and next-generation sequencing (NGS) for optimizing gene delivery has further accelerated research and commercial applications. As gene editing and cell-based therapies continue to expand, gene vector technology is expected to remain a cornerstone of genetic innovation.

What Are the Latest Technological Advancements in Gene Vector Development?

Recent technological advancements have significantly improved gene vector efficiency, specificity, and safety. One of the most notable breakthroughs is the development of next-generation AAV vectors with enhanced tissue tropism and reduced immunogenicity, allowing for targeted gene delivery with minimal side effects. Additionally, self-amplifying RNA (saRNA) vectors are gaining popularity in vaccine development, particularly in mRNA-based platforms, offering prolonged protein expression with lower doses.

In the realm of non-viral vectors, lipid nanoparticle (LNP) technology has revolutionized RNA therapeutics, providing a highly efficient and scalable method for delivering genetic material in vaccines and gene editing applications. AI-driven vector engineering has also improved the design of synthetic promoters, enhancing gene expression control and reducing off-target effects. Furthermore, advances in CRISPR-based gene editing have enabled the development of precision-guided vectors that can selectively edit specific genetic mutations without disrupting surrounding DNA sequences. These innovations are reshaping the gene vector landscape, making gene therapy safer, more effective, and more widely applicable.

What Factors Are Fueling the Growth of the Gene Vector Market?

The growth in the gene vector market is driven by several factors, including the rising prevalence of genetic disorders, increasing investment in gene therapy, and advancements in vector manufacturing technology. The success of FDA-approved gene therapies, such as Luxturna and Zolgensma, has demonstrated the clinical viability of gene vector-based treatments, prompting further research and development. Additionally, the demand for scalable and GMP-compliant vector production has led to the expansion of contract development and manufacturing organizations (CDMOs) specializing in viral and non-viral vector manufacturing.

The rise of personalized medicine and next-generation immunotherapies has also fueled the need for high-precision gene delivery systems. Regulatory agencies have introduced accelerated approval pathways for gene therapies, encouraging pharmaceutical companies to invest in advanced vector development. Furthermore, the integration of AI and computational modeling in vector optimization has enhanced efficiency and reduced production costs. As the demand for gene therapy continues to rise across oncology, neurology, and rare diseases, the gene vector market is expected to experience sustained growth, shaping the future of genetic medicine and biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Gene Vector market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector, Other Vector Types); Diseases (Oncology, Genetic Disorders, Infectious Diseases, Other Diseases); Application (Gene Therapy Application, Vaccinology Application, Other Applications); End-Use (CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use, CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • 4D Molecular Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Bluebird Bio
  • Catalent Biologics
  • Charles River Laboratories International Inc
  • CRISPR Therapeutics AG
  • Editas Medicine
  • FUJIFILM Holdings Corporation
  • Generation Bio
  • Intellia Therapeutics
  • Kaneka Corporation
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Oxford Biomedica plc
  • Rocket Pharmaceuticals
  • Sarepta Therapeutics
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Gene Vector - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rapid Growth of Gene Therapy and Vaccine Pipelines Drives Demand for High-Quality Gene Vectors
    • Increased Adoption of Viral Vectors for In Vivo Delivery Fuels Development of AAV, Lentivirus, and Adenovirus Platforms
    • Non-Viral Vectors Gain Traction Amid Safety Concerns and Manufacturing Challenges with Viral Vectors
    • OEM Focus on Enhancing Vector Yield, Stability, and Tropism Improves Therapeutic Delivery Outcomes
    • Rise in Genetic Disorders, Cancer Immunotherapies, and Rare Disease Programs Expands Application Scope for Gene Vectors
    • Regulatory Approval of First Commercial Gene Therapies Validates Clinical Potential and Market for Vectors
    • Investment in Vector Manufacturing Capacity and GMP-Grade Platforms Accelerates Global Supply Chain Development
    • Collaborations Between Biotech and CDMOs Enhance Process Development and Scale-Up Capabilities
    • Increased Demand for Custom Vector Engineering Fuels Innovation in Tissue-Specific and Inducible Expression Vectors
    • Shift Toward Synthetic and Modular Vector Platforms Supports Scalability and Cross-Therapeutic Use
    • Advancements in Vector Characterization, Quality Control, and Analytical Testing Improve Regulatory Compliance
    • OEM Integration of AI and Predictive Modeling Supports Rational Vector Design and Functional Optimization
    • Surge in mRNA and DNA-Based Vaccine Development Creates Synergies with Lipid and Polymer-Based Vectors
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gene Vector Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gene Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Plasmid DNA Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Plasmid DNA Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Plasmid DNA Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adenoviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adenoviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Adenoviral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adeno-Associated Viral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adeno-Associated Viral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adeno-Associated Viral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retroviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retroviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retroviral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Lentiviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Lentiviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Lentiviral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Vector Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Gene Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Vaccinology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Vaccinology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Vaccinology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for CDMOS End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for CDMOS End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for CDMOS End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 92: China Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Gene Vector by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 119: France Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 155: UK Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Gene Vector by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 230: India Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Gene Vector by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Gene Vector by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제